<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703311</url>
  </required_header>
  <id_info>
    <org_study_id>CB1-3</org_study_id>
    <nct_id>NCT02703311</nct_id>
  </id_info>
  <brief_title>REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System</brief_title>
  <acronym>REPAIR</acronym>
  <official_title>REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cardioband Transcatheter System (Cardioband) is indicated for the treatment of secondary&#xD;
      (functional) mitral regurgitation (FMR). The Cardioband is a transcatheter system, deployed&#xD;
      on the beating heart through a transseptal approach. The Cardioband is deployed along the&#xD;
      posterior annulus of the mitral valve (MV) and is adjusted under trans-esophageal guidance on&#xD;
      the beating heart. A CE mark study with 30 subjects has been completed and documented&#xD;
      reduction of severity of mitral regurgitation (MR) and improvement in 6- minute walk test in&#xD;
      subjects with moderate to severe MR.&#xD;
&#xD;
      Study objectives are to test the efficacy of the Cardioband in improving MR and heart failure&#xD;
      symptoms in patients with symptomatic (New York Heart Association (NYHA) Class III-IVa),&#xD;
      severe MR in the post-marketing setting, And to evaluate the safety of the Cardioband system&#xD;
      in the post-marketing setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Edwards acquired Valtech Cardio Ltd in 2017 and opted to replace this study with NCT03600688.11&#xD;
    patients were enrolled in REPAIR and follow-up is complete.&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Severity of MR at 30 Days of at Least One Category on a 0-4 Scale.</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Patients with Reduction in MR Severity of at least one grade at 30 days compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Distance Walked on 6 Minute Walk Test</measure>
    <time_frame>6 months over Baseline</time_frame>
    <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mitral Regurgitation Severity</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
    <description>Mitral Regurgitation at 6, 12, and 24 months compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Distance Walked on 6 Minute Walk Test</measure>
    <time_frame>12, and 24 months over baseline</time_frame>
    <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 12 and 24 months compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
    <description>Median KCCQ Score. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in New York Heart Association (NYHA) Class</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
    <description>NYHA Class at 6, 12, and 24 months compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume (LVEDV)</measure>
    <time_frame>6, 12, and 24 months over baseline</time_frame>
    <description>Median LVEDV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>6, 12, and 24 months over baselines</time_frame>
    <description>Median LVESV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Device Success</measure>
    <time_frame>Discharge</time_frame>
    <description>Device success is defined as deployment of the Cardioband, with MR reduction at hospital discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Patient Success</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Individual patient success (measured at 6 months and 1 year) defined as device success and the following:&#xD;
Discharged from index hospitalization&#xD;
NYHA class improvement by at least 1 level from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>12 months</time_frame>
    <description>Days alive and out of hospital due to major cardiovascular events at 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom From All-cause Mortality and Major Adverse Events (AE)</measure>
    <time_frame>30 days from implant procedure or hospital discharge, whichever is later.</time_frame>
    <description>Freedom from all-cause mortality and major AE is defined as disabling stroke, myocardial infarction (MI) (peri-procedural or spontaneous), renal failure requiring dialysis, life-threatening bleeding, cardiac tamponade and device related cardiac surgical intervention at 30 days from the implant procedure or hospital discharge, whichever is later.</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for Urgent/Emergent Surgical Intervention</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients who undergo urgent/emergent surgical intervention post procedure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Cardiac Valve Annuloplasty</condition>
  <condition>Mitral Valve Annuloplasty</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Cardioband procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardioband</intervention_name>
    <description>Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance</description>
    <arm_group_label>Cardioband procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Severe (3+ to 4+) secondary Mitral Regurgitation&#xD;
&#xD;
          3. Symptomatic heart failure (NYHA Class III-IVa) despite guideline directed medical&#xD;
             therapy including CRT if indicated&#xD;
&#xD;
          4. The Local Site Heart Team concur that surgery will not be offered as a treatment&#xD;
             option and that medical therapy is the intended therapy.&#xD;
&#xD;
          5. Transfemoral access and transseptal deployment of the Cardioband is determined to be&#xD;
             feasible&#xD;
&#xD;
          6. Subject is willing and able to provide informed consent and follow protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. EF &lt; 20%&#xD;
&#xD;
          2. LVEDD ≥ 70 mm&#xD;
&#xD;
          3. Heavily calcified annulus or leaflets&#xD;
&#xD;
          4. Significant CAD requiring revascularization&#xD;
&#xD;
          5. Active bacterial endocarditis&#xD;
&#xD;
          6. Any percutaneous coronary, carotid, endovascular intervention or carotid surgery&#xD;
             within 30 days or any coronary or endovascular surgery within 3 months&#xD;
&#xD;
          7. Renal insufficiency requiring dialysis&#xD;
&#xD;
          8. Life expectancy of less than twelve months&#xD;
&#xD;
          9. Subject is participating in concomitant research studies of investigational products&#xD;
             that have not reached their primary endpoint&#xD;
&#xD;
         10. Pulmonary hypertension ≥ 70mmHg at rest&#xD;
&#xD;
         11. Mitral valve anatomy which may preclude proper device treatment&#xD;
&#xD;
         12. Right-sided congestive heart failure with echocardiographic evidence of severe right&#xD;
             ventricular dysfunction and/or severe tricuspid regurgitation&#xD;
&#xD;
         13. Severe liver disease&#xD;
&#xD;
         14. Patient is pregnant or lactating&#xD;
&#xD;
         15. Hypersensitivity to Nickel or Chromium&#xD;
&#xD;
         16. Clinically significant bleeding diathesis or coagulopathy&#xD;
&#xD;
         17. History of mitral valve repair&#xD;
&#xD;
         18. TIA or CVA within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bichat hospital</name>
      <address>
        <city>Paris</city>
        <zip>18 75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bad Nauheim, Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bonn University</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik, St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>5 20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koln, Universitätsklinikum</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital san raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <results_first_submitted>September 3, 2020</results_first_submitted>
  <results_first_submitted_qc>October 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2020</results_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valtech Cardio</keyword>
  <keyword>Cardioband</keyword>
  <keyword>Mitral Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02703311/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardioband</title>
          <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30 Day Follow-Up Completed</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardioband</title>
          <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroScore II</title>
          <description>The European System for Cardiac Operative Risk Evaluation (EuroSCORE) II is a risk model which allows the calculation of the risk of death after a heart operation.&#xD;
EuroScore II risk levels are as follows:&#xD;
Low risk: &lt;8&#xD;
Moderate risk: 8-10&#xD;
High risk: &gt;10</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Functional Class III or IV</title>
          <description>NYHA Classification - The stages of heart failure:&#xD;
Class I - No symptoms and no limitation in ordinary physical activity.&#xD;
Class II - Mild symptoms and slight limitation during ordinary activity.&#xD;
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.&#xD;
Class IV - Severe limitations. Experiences symptoms even while at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ischemic Etiology of Regurgitation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dilated Cardiomyopathy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Coronary Artery Bypass Graft</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Renal Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paroxysmal, Persistent, Chronic Atrial Flutter/Fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Severity of MR at 30 Days of at Least One Category on a 0-4 Scale.</title>
        <description>Percentage of Patients with Reduction in MR Severity of at least one grade at 30 days compared to baseline</description>
        <time_frame>30 days</time_frame>
        <population>Intra-subject comparison of patients with paired data at baseline and 30 days</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Severity of MR at 30 Days of at Least One Category on a 0-4 Scale.</title>
          <description>Percentage of Patients with Reduction in MR Severity of at least one grade at 30 days compared to baseline</description>
          <population>Intra-subject comparison of patients with paired data at baseline and 30 days</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Distance Walked on 6 Minute Walk Test</title>
        <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 6 months compared to baseline</description>
        <time_frame>6 months over Baseline</time_frame>
        <population>Intra-subject comparison of patients with paired data at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distance Walked on 6 Minute Walk Test</title>
          <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 6 months compared to baseline</description>
          <population>Intra-subject comparison of patients with paired data at baseline and 6 months</population>
          <units>Meters</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mitral Regurgitation Severity</title>
        <description>Mitral Regurgitation at 6, 12, and 24 months compared to baseline</description>
        <time_frame>6, 12, and 24 months over baseline</time_frame>
        <population>This planned endpoint of change mitral regurgitation severity in was unable to be analyzed due to the small sample size that was achieved in this study. Data available at each time point were reported as number of patients with MR grades None/Trace, Mild, Moderate, Severe.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitral Regurgitation Severity</title>
          <description>Mitral Regurgitation at 6, 12, and 24 months compared to baseline</description>
          <population>This planned endpoint of change mitral regurgitation severity in was unable to be analyzed due to the small sample size that was achieved in this study. Data available at each time point were reported as number of patients with MR grades None/Trace, Mild, Moderate, Severe.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None/Trace</title>
                </category>
                <category>
                  <title>Mild</title>
                </category>
                <category>
                  <title>Moderate</title>
                </category>
                <category>
                  <title>Severe</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Distance Walked on 6 Minute Walk Test</title>
        <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 12 and 24 months compared to baseline</description>
        <time_frame>12, and 24 months over baseline</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distance Walked on 6 Minute Walk Test</title>
          <description>Median distance in meters walked during 6 Minute Walk Test (6MWT) at 12 and 24 months compared to baseline</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>Median KCCQ Score. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status.</description>
        <time_frame>6, 12, and 24 months over baseline</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>Median KCCQ Score. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status.</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in New York Heart Association (NYHA) Class</title>
        <description>NYHA Class at 6, 12, and 24 months compared to baseline</description>
        <time_frame>6, 12, and 24 months over baseline</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in New York Heart Association (NYHA) Class</title>
          <description>NYHA Class at 6, 12, and 24 months compared to baseline</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Left Ventricular End Diastolic Volume (LVEDV)</title>
        <description>Median LVEDV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
        <time_frame>6, 12, and 24 months over baseline</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume (LVEDV)</title>
          <description>Median LVEDV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Median LVESV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
        <time_frame>6, 12, and 24 months over baselines</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Median LVESV data, as measured by TTE at 6, 12, and 24 months compared to baseline</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Device Success</title>
        <description>Device success is defined as deployment of the Cardioband, with MR reduction at hospital discharge.</description>
        <time_frame>Discharge</time_frame>
        <population>The outcome is reported for subjects where data is available. Subjects with missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Device Success</title>
          <description>Device success is defined as deployment of the Cardioband, with MR reduction at hospital discharge.</description>
          <population>The outcome is reported for subjects where data is available. Subjects with missing data are excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Patient Success</title>
        <description>Individual patient success (measured at 6 months and 1 year) defined as device success and the following:&#xD;
Discharged from index hospitalization&#xD;
NYHA class improvement by at least 1 level from baseline</description>
        <time_frame>6 and 12 months</time_frame>
        <population>The outcome is reported for subjects where data is available. Subjects with missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Patient Success</title>
          <description>Individual patient success (measured at 6 months and 1 year) defined as device success and the following:&#xD;
Discharged from index hospitalization&#xD;
NYHA class improvement by at least 1 level from baseline</description>
          <population>The outcome is reported for subjects where data is available. Subjects with missing data are excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>Days alive and out of hospital due to major cardiovascular events at 1 year</description>
        <time_frame>12 months</time_frame>
        <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive and Out of Hospital</title>
          <description>Days alive and out of hospital due to major cardiovascular events at 1 year</description>
          <population>This planned endpoint was unable to be analyzed due to the small sample size that was achieved in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Freedom From All-cause Mortality and Major Adverse Events (AE)</title>
        <description>Freedom from all-cause mortality and major AE is defined as disabling stroke, myocardial infarction (MI) (peri-procedural or spontaneous), renal failure requiring dialysis, life-threatening bleeding, cardiac tamponade and device related cardiac surgical intervention at 30 days from the implant procedure or hospital discharge, whichever is later.</description>
        <time_frame>30 days from implant procedure or hospital discharge, whichever is later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-cause Mortality and Major Adverse Events (AE)</title>
          <description>Freedom from all-cause mortality and major AE is defined as disabling stroke, myocardial infarction (MI) (peri-procedural or spontaneous), renal failure requiring dialysis, life-threatening bleeding, cardiac tamponade and device related cardiac surgical intervention at 30 days from the implant procedure or hospital discharge, whichever is later.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Need for Urgent/Emergent Surgical Intervention</title>
        <description>Number of patients who undergo urgent/emergent surgical intervention post procedure</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardioband</title>
            <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Urgent/Emergent Surgical Intervention</title>
          <description>Number of patients who undergo urgent/emergent surgical intervention post procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cardioband</title>
          <description>Patients who were enrolled and had the Cardioband procedure attempted</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>One patient experienced two Atrial Fibrillation adverse events (one serious and one non-serious). Both episodes are reported for this patient, one under Serious Adverse Events and the other under Other (Not Including Serious) Adverse Events.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dermohypodermitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IIIrd Nerve Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage Urinary Tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Heparin Induced Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>One patient experienced two Atrial Fibrillation adverse events (one serious and one non-serious). Both episodes are reported for this patient, one under Serious Adverse Events and the other under Other (Not Including Serious) Adverse Events.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Puncture Site Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creactive Protein Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed Level of Conciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Pacing Issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ted Feldman</name_or_title>
      <organization>Edwards Lifesciences</organization>
      <phone>949-250-2500</phone>
      <email>Feldman_Info@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

